CN104168908A - 罗米地新制剂及其用途 - Google Patents

罗米地新制剂及其用途 Download PDF

Info

Publication number
CN104168908A
CN104168908A CN201380013811.9A CN201380013811A CN104168908A CN 104168908 A CN104168908 A CN 104168908A CN 201380013811 A CN201380013811 A CN 201380013811A CN 104168908 A CN104168908 A CN 104168908A
Authority
CN
China
Prior art keywords
romidepsine
cancer
administered
preparation
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380013811.9A
Other languages
English (en)
Chinese (zh)
Inventor
联丰·黄三世
许浩华
维克托·佩科夫
威拉德·R·福斯
维贾伊·纳林格瑞卡
梅·拉伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN104168908A publication Critical patent/CN104168908A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380013811.9A 2012-01-12 2013-01-11 罗米地新制剂及其用途 Pending CN104168908A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586066P 2012-01-12 2012-01-12
US61/586,066 2012-01-12
PCT/US2013/021212 WO2013106696A1 (en) 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof

Publications (1)

Publication Number Publication Date
CN104168908A true CN104168908A (zh) 2014-11-26

Family

ID=47604232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013811.9A Pending CN104168908A (zh) 2012-01-12 2013-01-11 罗米地新制剂及其用途

Country Status (8)

Country Link
US (3) US20130184225A1 (cg-RX-API-DMAC10.html)
EP (1) EP2802340B1 (cg-RX-API-DMAC10.html)
JP (1) JP6170946B2 (cg-RX-API-DMAC10.html)
CN (1) CN104168908A (cg-RX-API-DMAC10.html)
AU (1) AU2013201937B8 (cg-RX-API-DMAC10.html)
CA (1) CA2863291A1 (cg-RX-API-DMAC10.html)
MX (1) MX2014008390A (cg-RX-API-DMAC10.html)
WO (1) WO2013106696A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106137980A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种罗米地辛脂微球制剂及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630311A (en) * 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US20210169871A1 (en) * 2018-04-05 2021-06-10 Tarveda Therapeutics, Inc. Pharmaceutical compositions with reduced tert-butanol levels

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1040054A (zh) * 1988-07-26 1990-02-28 藤泽药品工业株式会社 具有生物活性的新化合物及其制备方法
CN101212982A (zh) * 2005-06-02 2008-07-02 南安普敦大学 作为hdac抑制剂的fk228衍生物
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
ATE294571T1 (de) * 1999-03-03 2005-05-15 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
CN103497238A (zh) * 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
JP2010105965A (ja) * 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1040054A (zh) * 1988-07-26 1990-02-28 藤泽药品工业株式会社 具有生物活性的新化合物及其制备方法
CN101212982A (zh) * 2005-06-02 2008-07-02 南安普敦大学 作为hdac抑制剂的fk228衍生物
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106137980A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种罗米地辛脂微球制剂及其制备方法

Also Published As

Publication number Publication date
US20160367625A1 (en) 2016-12-22
WO2013106696A1 (en) 2013-07-18
EP2802340B1 (en) 2020-10-28
JP2015503623A (ja) 2015-02-02
AU2013201937B2 (en) 2015-07-30
AU2013201937A1 (en) 2013-08-01
US20150051157A1 (en) 2015-02-19
EP2802340A1 (en) 2014-11-19
AU2013201937B8 (en) 2015-08-20
JP6170946B2 (ja) 2017-07-26
US20130184225A1 (en) 2013-07-18
MX2014008390A (es) 2014-09-22
AU2013201937A8 (en) 2015-08-20
CA2863291A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
JP5645667B2 (ja) 増殖性疾患を治療するための、Ｎ−（５−ｔｅｒｔ−ブチル−イソキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，ｌ−ｂ］［ｌ，３］ベンゾチアゾール−２−イル］フェニル｝尿素の投与方法
ES2773315T3 (es) Formulación de AC220 secada por pulverización
US20160367625A1 (en) Romidepsin formulations and uses thereof
TW202227090A (zh) 四環喹諾酮類似物及其鹽類的藥物組合物
US9782451B2 (en) Romidepsin formulations and uses thereof
CN101665449B (zh) 他米巴罗汀的水溶性前药及其制备方法与应用
CN107921004A (zh) 包含3‑(5‑氨基‑2‑甲基‑4‑氧代基‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮的药物组合物
EP4282408A1 (en) Method for pretreating relapsing cancer
CN119233821A (zh) Pi3k抑制剂与pd-1抑制剂的组合疗法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141126